Introduction

Through didactic presentations, interactive panel discussions, and QandA sessions, the 2.5 day conference will serve as a platform to discuss and evaluate many of the clinical challenges for optimal integration of anti-angiogenesis and immune-modulating agents into existing treatment paradigms for cancer care, appropriate selection of patients based on biomarker profiles for individualized treatment strategies, and use of these agents in the adjuvant and advanced disease settings.

Featuring presentations from more than 25 investigators, sessions will include:
Basic Science: Update on Angiogenesis
Basic Science: Update on Tumor Immunology
Crosstalk in Tumor Immunology and Preclinical Modeling
Novel Approaches to Activate the Immune Response to Tumor Antigens
Controversies with New Therapeutics Targeting Angiogenesis and Tumor Immunology
Biomarkers and Predictors of Response
Overview of Clinical Trials of AgentsTargeting Angiogenesis and Tumor Immunology: Clinical Trial Overview

Focusing on both clinical and basic research, topics will focus on cutting edge science in the field, highlighting novel strategies under both pre-clinical and clinical development. We encourage clinicians, scientists, and other healthcare professionals who work in the area of tumor immunology to attend.

Deep discounts are available right now, but expire soon. Rates start as low as $100 for the full conference.

Useful links

• Further event details More information about the event

Venue

Hyatt Regency La Jolla

Hyatt Regency La Jolla, 3777 La Jolla Village Drive, San Diego, 92122, United States

Contact information

Tradd Sanderson
Imedex
4047841276
Contact us by email

---